Smart
inhalers are devices, used for delivering various medications through
inhalation. It is mainly a respiratory inhaler, equipped with a digital sensor,
also known as connected inhalers. The sensor tracks data such as dosage timing,
monitors the use of inhaler, and schedules the next dosage. These inhalers are
able to generate alerts for daily dosage using smart devices like tablets or
phones connected to the sensors via Bluetooth technology. These are designed to
treat respiratory disorders such as chronic obstructive pulmonary diseases
(COPD) and asthma. Some drugs are used in the inhalers include glucocorticoids,
anti-cholinergic, beta-agonists and insulin etc.
According
to study, “Global
Smart Inhalers Market Size study, by product (inhalers and nebulizers),
Indication (COPD and asthma), End-user (patients and R&D) and Regional
Forecasts 2018-2025” the key companies operating in the global smart
inhalers market are Teva Pharmaceuticals Industries Ltd., Boehringer Ingelheim
GmbH, Vectura Group PLC, ResMed Inc. (Propeller Health), AstraZeneca PLC,
Adherium Limited, Inspiro Medical Ltd., H&T Presspart Manufacturing Ltd.,
Aptar Pharma (AptarGroup, Inc.), Gecko Health Innovations, Inc., Cohero Health
LLC, Glaxo SmithKine PLC, Novartis International AG, OPKO Health Inc., 3M Drug
Delivery Systems, Crux Product Design Ltd, e-pill LLC, Glenmark
Pharmaceuticals, OMRON Healthcare Europe B.V, PARI GmbH, Tri-Med Inc., Philips
Respironics, Qualcomm Life, Shenzhen Bi-Rich Medical Devices Co., Ltd.,
Sensirion AG. The leading manufacturers are focusing on collaborating with
digital & software companies in order to serve the targeted population.
Furthermore, such collaborations also help manufacturers to launch their
products more conveniently as well as augment their distribution channels.
Based
on product type, smart inhalers market is segmented into nebulizers and
inhalers. Inhalers segment is further sub-segmented into metered dose inhalers
(MDIs) and dry powder inhalers (DPIs). MDIs maintain the amount of dosage used
per inhalation for medication while DPIs deliver medications for instance
corticosteroids directly to the lungs and are breathe activated. Based on
indication type, market is segmented into COPD and asthma. Based on
distribution channel, market is segmented into retail pharmacies, hospital
pharmacies and online pharmacies. In addition, based on end-use, market is
segmented into hospitals & clinics, research institute and respiratory care
centers.
The
smart inhalers market is driven by increase in air pollution, followed by rise
in prevalence of COPD and asthma diseases, increase in population susceptible
to indoor air pollutants and technological advancements in the development of
better smart inhaler devices & systems. However, overall high cost of asthma
and COPD treatment and misusing data & data privacy may impact the market.
Moreover, increase in focus towards advanced treatment protocols is a key
opportunity for market.
Based
on geography, the North-American region holds major share, followed by European
region in smart inhalers market owing to high awareness about the use of
digital devices for appropriate disease management, rise in adoption of smart
inhaler device, high technological innovations in healthcare sector, and growth
in adoption of IOT in healthcare industry in the region. The Asian-Pacific
region is expected to witness higher growth rate due to growth in population
affected with respiratory diseases caused by rise in air pollution over the
forecast period. It is projected that the market will be reached at US $829.3
million by 2025.
To
know more, click on the link below:-
Contact
Us:-
Ken
Research
Ankur
Gupta, Head Marketing & Communications
+91-9015378249
No comments:
Post a Comment